# Recursion Pharmaceuticals

Recursion Pharmaceuticals is an Asset Manager based in Salt Lake City, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Salt Lake City, United States
- **Region:** North America
- **Address:** Salt Lake City, UT, United States
- **Assets under management:** Undisclosed
- **Website:** recursion.com

## Regulatory record

- **Reports private funds:** No

## About

Dive into Recursion's innovative approach to decoding biology. Join our mission & explore what AI drug discovery companies can do. Contact us today!

## Sectors

- Digital Health
- AI/ML
- Healthcare Services

## People

- Chris Gibson — Co-Founder & Chairman of the Board
- Najat Khan — Chief Executive Officer

## Questions

### Who leads Recursion's drug discovery strategy?

Najat Khan serves as CEO, while Chris Gibson — the co-founder who originated the cellular imaging approach — remains chairman. The executive team oversees distinct research, clinical, and technology functions that feed the Recursion OS platform. The firm lists ten board members with deep biotech and AI expertise.

### How does Recursion's discovery platform differ from traditional pharma?

Recursion replaces hypothesis-driven discovery with a high-throughput, image-based phenomics engine. Computer vision extracts features from millions of cell experiments, and machine-learning models map those features to disease biology. This closed loop permits rapid target identification, lead optimization, and safety screening.

### What clinical-stage programs is Recursion advancing?

The pipeline includes REC-3565, a MALT1 inhibitor in Phase 1 for B-cell lymphomas, and studies targeting solid tumors such as ELUCIDATE and DAHLIA. The company focuses on first-in-class and best-in-class therapies for aggressive cancers and rare diseases with high unmet need.

### Does Recursion partner with other organizations?

Yes. Recursion pursues pharmaceutical partnerships, technology collaborations (notably with NVIDIA, which co-built the BioHive-2 supercomputer), and data partnerships that augment its proprietary datasets. These alliances help accelerate discovery and extend the platform's reach.

### How large is Recursion's proprietary dataset?

As disclosed by the firm, the dataset exceeds 50 petabytes across phenomics, transcriptomics, proteomics, ADME, and de-identified patient records. Automated labs in Salt Lake City continuously generate new data, which feeds back into the Recursion OS models.

## Related profiles

- [Riviera Partners](https://altss.com/profile/riviera-partners)
- [GNI Ltd.](https://altss.com/profile/gni-ltd)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/recursion-pharmaceuticals

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology